Angiotensin II receptor antagonists – we have moved closer to the patient
Abstract
Aim. To investigate antihypertensive efficacy of losartan (Lozap®), as monotherapy and in combination with a diuretic hydrochlorothiazide (Lozap® Plus), according to its influence on circadian blood pressure profile (CBPP) in patients with arterial hypertension (AH).
Material and methods. In 25 patients with Stage I-II AH, the influence of 8-week Lozap® monotherapy (n=12), 50 mg/d, and its fixed-dose combination with hydrochlorothiazide, Lozap® Plus (n=13), on CBPP was studied. Office BP (BPo) measurement, and 24-hour BP monitoring (BPM) were performed.
Results. After 4 weeks of Lozap® monotherapy, BPo decreased by -8.4±10.7/-11.2±10.7 mm Hg (p<0.001); target BP level was reached in 48% of participants. By Week 8, BPo decreased by -13.0±9.0/-5.8±9.2 mm Hg (p<0.0001/0.01); target BP level was achieved in 92% of the patients. According to 24-hour BPM, daytime BP decreased by -22.3±12.1/13.8±11.2 mm Hg (р<0.0001), nighttime BP - by -25.9±16.7/16.4±11.3 mm Hg (р<0.0001). Daytime, nighttime, and 24-hour target BP levels were reached in 80%, 72%, and 88% of the participants, respectively. Т/Р ratio 71.6%/72.9% is an evidence of sufficient, even antihypertensive effect of Lozap® and Lozap® Plus. These medications significantly increased nighttime BP decline and normalized BP circadian rhythm (CP) in most patients. The therapy was well tolerated, with minimal adverse reactions, and side effects.
Conclusion. Antihypertensive therapy with Lozap® and Lozap® Plus provides prolonged and even antihypertensive effect, corrects CBPP by reducing pressure workload, pulse BP, and improving BP CR. The maximal-dose therapy gives an opportunity to achieve target BP levels in 92% of the patients.
About the Authors
L. G. Ratova
A.L. Myasnikov Clinical Cardiology Institute, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
I. P. Kolos
A.L. Myasnikov Clinical Cardiology Institute, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
I. E. Chazova
A.L. Myasnikov Clinical Cardiology Institute, Russian Cardiology Scientific and Clinical Complex, Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Арабидзе Г.Г., Белоусов Ю.Б., Варакин Ю.Я. и др. Диагностика и лечение артериальной гипертонии (Методические рекомендации). Москва 1997: 95с.
2. Chobanian A, Bakris G, Black H, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
3. Almazov VA, Shlyakhto EV, Conrady AO, et al. Correlation of hypertensive cardiac remodeling: comparision of different antihypertensive therapies. J Hypertens 1999; 17(3): 194.
4. Mancia G. Blood pressure variability: mechanisms and clinical significance. J Cardiovasc Pharmacol 1990; 16(Suppl 6): 1S-6.
5. Perloff D, Sokolow M, Cowan R, et al. Prognostic value of ambulatory blood pressure monitoring in treated hypertensive patients. J Hypertens 1991; 9: 33-40.
6. Verdecchia P, Porcelatti C, Schilattci G, et al. Ambulatory blood pressure an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
7. Verdecchia P, Schillaci G, Guerieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-36.
8. Parati O, Omboni B, Di Rienzo M, et al. Twenty-four hour blood pressure variability: clinical implications. Kidney Internat 1992; 41: 24-8.
9. Schmieder RE, Martus P, Klingbeil A. Reversal of LVH in essential hypertension: meta- analysis of randomized double-blind studies. JAMA 1996; 275(19): 1507-13.
10. Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Российские рекомендации (второй пересмотр). Комитет экспертов Всероссийского научного общества кардиологов. Секция артериальной гипертонии ВНОК. Москва 2004.
11. 1999 Guideliness of the management of mild hypertension: Memorandum from the World Health Organization/International Society of Hypertension Meeting Guidelines Subcommittee. J Hypertens 1999; 17: 151-83.
12. Ратова Л.Г., Дмитриев В.В., Толпыгина С.Н., Чазова И.Е. Суточное мониторирование артериального давления в клинической практике. Cons med, приложение «Артер гипер» 2001: 3-14.
13. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. и др. Суточное мониторирование артериального давления (Методические вопросы). Под ред. Г.Г. Арабидзе и О.Ю. Атькова. М. 1997.
14. Burt VL, Cutler JA, Higgins M, et al. Trends in the prevalence, awareness, treatment and control of hypertension in the adult US population. Data from the Health examination surveys. 960- 1991. Hypertension 1995; 26(1): 60-9.
15. Kannel W. Potency of vascular risk factors as the basis for antihypertensive therapy. Framingham study. Eur Heart J 1992; 13: 34-42.
16. Somers V, Dyken M, Mark A, et al. Autonomic and hemodynamic responses during sleep in normal and sleep-apneic humans. J Hypertens 1992; 10: 4.
17. Fratolla A, Parati G, Cuspidi C, et al. Prognostic value of 24- hour pressure variability. J Hypertens 1993; 11: 1133-7.
18. Staessen JA, Bieniaszewski L, O’Brien ET, et al. An epidemiologic approach to ambulatory blood pressure monitoring: the Belgian population study. Blood Press Monit 1996; 1(1): 13-26.
19. Staessen JA, Bieniaszewski L, O’Brien ET, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension 1997; 29: 30-9.
20. Verdecchia P, Clement D, Fagard R, et al. Target-organ damage, morbidity and mortality. Blood Pre Monit 1999; 4: 303-17.
Review
For citations:
Ratova L.G., Kolos I.P., Chazova I.E. Angiotensin II receptor antagonists – we have moved closer to the patient. Cardiovascular Therapy and Prevention. 2005;4(2):40-45. (In Russ.)
Views:
418
Email this article 
